Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis

被引：1
|
作者：
Chang, Hui-Chin [1 ,2 ,3 ]
Gau, Shuo-Yan [3 ,4 ]
机构：
[1] Chung Shan Med Univ Hosp, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Evidence Based Med Ctr, Taichung, Taiwan
[3] Chung Shan Med Univ, Sch Med, 110 Sec 1, Jianguo N Rd, Taichung 40201, Taiwan
[4] Chi Mei Med Ctr, Inst Med Educ, Tainan, Taiwan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 58卷 / 11-12期
关键词：
D O I：
10.1111/apt.17697
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to Kochhar et al papers. To view these articles, visit and
引用
收藏
页码：1242 / 1242
页数：1
相关论文
共 50 条
  • [21] Predictors of the efficacy of vedolizumab in patients with ulcerative colitis
    Kajikawa, Go
    Sawada, Tsunaki
    Nakamura, Masanao
    Yamamura, Takeshi
    Maeda, Keiko
    Ishikawa, Eri
    Uetsuki, Kota
    Hirose, Takashi
    Iida, Tadashi
    Mizutani, Yasuyuki
    Yamao, Kentaro
    Ishikawa, Takuya
    Furukawa, Kazuhiro
    Kawashima, Hiroki
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (03): : 407 - 421
  • [22] Tofacitinib for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (07): : 475 - 475
  • [23] Tofacitinib in ulcerative colitis
    Archer, Thomas P.
    Moran, Gordon W.
    Ghosh, Subrata
    IMMUNOTHERAPY, 2016, 8 (05) : 495 - 502
  • [24] Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
    Iborra, M.
    Soutullo, C.
    Gimeno, M.
    Bastida, G.
    Aguas, M.
    Cerrillo, E.
    Saez-Gonzalez, E.
    Garrido, A.
    Minguez, A.
    Bordetas, J.
    Nos, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I383 - I384
  • [25] Ustekinumab as an opportunity for refractory Ulcerative Colitis patients
    Iborra, M.
    Soutullo, C.
    Gimeno, M.
    Bastida, G.
    Aguas, M.
    Cerrillo, E.
    Saez-Gonzalez, E.
    Garrido, A.
    Minguez, A.
    Bordetas, J.
    Nos, P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I383 - I384
  • [26] The role and prospect of tofacitinib in patients with ulcerative colitis
    Lee, Jun
    INTESTINAL RESEARCH, 2022,
  • [27] SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS
    Chaaban, Lara
    Huang, Jane
    Melia, Joanna
    GASTROENTEROLOGY, 2024, 166 (03) : S115 - S115
  • [28] LOWER INCIDENCE OF HERPES ZOSTER IN VEDOLIZUMAB-TREATED VS TOFACITINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS
    Caldera, Freddy
    Lasch, Karen
    Cao, Charlie
    Bhayat, Fatima
    GASTROENTEROLOGY, 2018, 154 (06) : S994 - S994
  • [29] Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
    Adimadhyam, Sruthi
    Lewis, James D.
    Simon, Andrew L.
    Wolfe, Audrey E.
    Smith, Samantha
    Hou, Laura
    Moyneur, Erick
    Reynolds, Juliane S.
    Toh, Sengwee
    Dobes, Angela
    Parlett, Lauren
    Haynes, Kevin
    Burris, Jessica
    Dorand, Jennifer E.
    Long, Millie D.
    Kappelman, Michael D.
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (04) : 554 - 562
  • [30] A comparison of vedolizumab and ustekinumab treatment in patients with Ulcerative Colitis after failure of treatment with tumor necrosis factor inhibitor
    Wiken, T. E. Helm
    Hoivik, M. L.
    Buer, L.
    Warren, D. J.
    Bolstad, N.
    Anisdahl, K.
    Lundekvam, J.
    Hagen, M.
    Medhus, A. W.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1609 - I1609
12345